Abstract
This article contains edited extracts from a report for the UK Biotechnology Directorate. One of the main findings of the report was the extreme volatility of the whole sector; firms were producing interesting and path-breaking research, yet the governmental support apparatus was having some difficulty in providing clear, relevant and widely publicized schemes to help small and medium-sized firms (SMEs) maximize the potential of their research.
Get full access to this article
View all access options for this article.